|
Aug 7
|
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
|
|
Aug 6
|
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
|
|
Aug 4
|
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
|
|
Aug 1
|
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 1
|
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
|
|
Jul 31
|
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
|
|
Jul 25
|
H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy
|
|
Jul 22
|
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share
|
|
Jul 1
|
Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials
|
|
Jun 29
|
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
|
|
May 1
|
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 1
|
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
|
|
May 1
|
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
|
|
Mar 16
|
US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results
|
|
Mar 14
|
Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...
|
|
Mar 14
|
Q4 2024 Akebia Therapeutics Inc Earnings Call
|
|
Mar 13
|
Sector Update: Health Care Stocks Slipping Late Afternoon
|
|
Mar 13
|
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 13
|
Akebia Therapeutics: Q4 Earnings Snapshot
|
|
Mar 13
|
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
|